Nuritas Brings AI-Designed Peptides
to the Dairy Aisle With PeptiStrong
At IFT FIRST 2026 in Chicago, the Dublin biotech unveiled a frozen yoghurt built around a clinically validated, fava bean-derived peptide — a signal that AI-discovered functional ingredients are moving out of capsules and into mainstream food formats.
A Peptide Built for the Freezer Aisle
At the IFT FIRST 2026 conference in Chicago earlier this month, Irish biotech Nuritas presented one of the more unusual applications yet for its flagship ingredient: a frozen yoghurt formulated around PeptiStrong®, a clinically validated peptide blend designed to support muscle health. The prototype was built to demonstrate a broader point the company has been pushing since its founding — that functional nutrition no longer needs to live inside a capsule or a powder tub.
PeptiStrong is derived from fava beans and discovered using Nuritas' proprietary AI platform, Magnifier, which the company says can identify and validate cell-signalling peptides far faster than conventional discovery methods. The ingredient's core commercial promise is versatility: it has been shown to remain heat-stable across a wide pH range and to survive upper-gut digestion in in-vitro studies, meaning it can be processed into dairy, bakery, and beverage formats without losing bioactivity — a persistent obstacle for peptide and protein ingredients used in real-world food manufacturing.
Key Takeaways
- Nuritas showcased PeptiStrong-infused frozen yoghurt at IFT FIRST 2026, part of a wider push to move its peptides from supplement formats into mainstream food and beverage applications.
- In a 56-day clinical trial with 72 participants, PeptiStrong was linked to a significant increase in leg strength, adding to the ingredient's existing clinical support for muscle recovery and energy.
- The ingredient's heat stability across processing conditions — including retort and UHT — makes it commercially viable for dairy, bakery, and RTD beverage manufacturers, not just capsules or powders.
- Nuritas holds partnerships with L'Oréal, GNC, Novo Nordisk, Nestlé, and Mars, spanning food, supplement, and personal-care categories.
- For MENA food manufacturers, the shift toward AI-discovered, clinically backed functional ingredients points to a widening opportunity in active-nutrition dairy and snacking — categories central to Saudi Arabia's growing health and wellness market.
The Clinical Case Behind the Concept
Nuritas' pitch to formulators rests heavily on clinical substantiation, an increasingly decisive factor for functional-ingredient buyers navigating a crowded and often unsubstantiated wellness market. In a 56-day trial involving 72 participants, PeptiStrong was associated with a significant increase in leg strength, building on earlier company-cited research linking the peptide to improved strength recovery and reduced fatigue. The company has positioned these results alongside comparisons to muscle protein synthesis benchmarks, aiming to differentiate PeptiStrong from generic plant-protein claims.
That evidence base matters commercially. PeptiStrong reportedly carries FDA GRAS status in the United States and Non-Novel Food designation in Canada and the European Union, giving manufacturers a comparatively de-risked regulatory pathway into more than 20 markets. Nuritas has said the ingredient is already present in over 100 commercial product launches globally, spanning supplements, functional foods, and beverages.
"-Functional benefits do not have to be confined to capsules or powder blends. At IFT, we are showing how our peptide hydrolysates can move into yoghurt, beverages, crisps, and bakery, all while maintaining bioavailability throughout processing."
An AI Discovery Platform With Broad Industrial Reach
Nuritas was founded in Dublin in 2014 and has built its business around applying artificial intelligence and genomics to identify naturally occurring bioactive peptides in plant sources, rather than synthesizing novel compounds from scratch. That approach has attracted a client roster spanning food, supplement, and personal-care categories, including L'Oréal, GNC, Novo Nordisk, Nestlé, and Mars, alongside earlier collaborations with Givaudan, BASF, and Sumitomo Corporation.
The company closed an oversubscribed $42 million Series C round in December 2024, led by M&G Investments and McWin Capital Partners, taking its total funding above $117 million. Alongside PeptiStrong, Nuritas markets PeptiSleep, a brown rice-derived peptide targeting cortisol-linked sleep disruption, and PeptiYouth, aimed at skin health — evidence of a platform strategy built to generate multiple ingredient franchises from the same underlying discovery engine rather than a single hero product.
Why the Format Matters More Than the Ingredient
The frozen yoghurt prototype is arguably more significant as a formulation statement than as a product launch. Functional ingredient suppliers have spent years working to move active-nutrition claims out of capsules and into everyday food formats, but doing so without degrading the active compound during processing — particularly under retort or UHT conditions — has been a persistent technical barrier. Nuritas' emphasis on heat and pH stability is a direct response to that constraint, and it reflects where competitive advantage in functional ingredients increasingly sits: not just in the biological activity of a compound, but in its manufacturability at scale.
This also reflects a broader shift in functional nutrition demand. Consumers, particularly younger and more health-literate shoppers, are increasingly drawn to everyday formats — yoghurt, snacks, beverages — that deliver a functional benefit without requiring a change in existing eating habits. Ingredient suppliers that can credibly deliver active compounds through familiar food formats, backed by clinical data rather than marketing claims alone, are positioned to capture a larger share of that demand than those still tied to supplement-only delivery systems.
Relevance to Saudi Arabia and the MENA Region
For food and beverage manufacturers across Saudi Arabia and the wider Gulf, the shift toward clinically validated, AI-discovered functional ingredients is directly relevant to two fast-growing categories: functional dairy and active-nutrition snacking. Saudi consumers have shown rising appetite for high-protein and fortified dairy products, and local manufacturers seeking to differentiate on health credentials — rather than compete purely on price — stand to benefit from access to ingredients with strong regulatory and clinical backing.
The case also carries a Vision 2030 dimension. As the Kingdom continues to invest in domestic food manufacturing capacity and reduce reliance on imported finished goods, access to internationally validated, technically de-risked functional ingredients becomes a meaningful enabler for local producers looking to launch differentiated products rather than private-label commodity lines. Partnerships or licensing arrangements with platforms like Nuritas — which has already shown a willingness to work across food, supplement, and personal-care categories — represent one plausible pathway for regional manufacturers to accelerate entry into functional and active-nutrition segments.
Editorial View
Nuritas' frozen yoghurt prototype is a small product, but it captures a larger transition underway in functional ingredients: AI-driven discovery is no longer just accelerating how peptides are found — it is reshaping where they can credibly be delivered. As clinical substantiation becomes table stakes for functional claims, and as regulatory clearance across 20-plus markets lowers the barrier to entry, ingredient platforms that combine scientific rigor with manufacturing flexibility are best placed to convert lab-stage discovery into shelf-stable, mainstream products. For MENA food companies watching global functional-nutrition trends closely, that combination is worth tracking.
